Eiko Lifesciences Ltd Stock Price Today (NSE: EIKO)

Eiko Lifesciences Ltd

52.95+0.63 (+1.20%)
Market Closed

Fundamental Score

...

Eiko Lifesciences Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Eiko Lifesciences Ltd share price today is 52.95, up +1.20% on NSE/BSE as of 19 June 2026. Eiko Lifesciences Ltd (EIKO) is a Small-cap company in the Specialty Chemicals sector with a market capitalisation of 69.89 (Cr). The 52-week high for EIKO share price is 65.90 and the 52-week low is 45.90. At a P/E ratio of 21.63x, EIKO is currently trading below its industry average P/E of 29.20x.

Eiko Lifesciences Ltd Share Price Chart — NSE/BSE Historical Performance

No data
High
56.35
Low
48.00
Volume
11.8K
Change
+6.28%

Eiko Lifesciences Ltd share price chart: 6.28% return over the past month. 52-week high ₹65.90, 52-week low ₹45.90.

Eiko Lifesciences Ltd — Last 10 Trading Days

DateOpenHighLowCloseVolume
52.8753.9551.1652.9511.31K (Cr)
53.4453.4451.0052.329.37K (Cr)
54.0054.6052.0252.1517.79K (Cr)
53.9856.3553.0253.3140.20K (Cr)
49.9355.9049.8553.0380.93K (Cr)
49.2049.5548.6549.3810.16K (Cr)
49.1749.8949.1749.571.25K (Cr)
49.8050.8048.9949.4825.64K (Cr)
49.5849.9449.0049.055.95K (Cr)
49.0650.4949.0149.752.25K (Cr)

Eiko Lifesciences Ltd — Last 12 Months Price History

MonthOpenHighLowCloseChange
53.4453.9551.0052.95-0.92%
50.4656.3548.0052.15+3.35%
50.9855.0049.0050.46-1.02%
52.5055.8845.9049.74-5.26%
54.6654.6649.0051.46-5.85%
54.0055.9848.0253.90-0.19%
52.3059.0048.0055.05+5.26%
58.0064.4450.0052.14-10.10%
53.2557.9949.8656.35+5.82%
51.0557.9050.5653.25+4.31%
57.5057.5051.0051.22-10.92%
49.5665.9048.2156.51+14.02%

AI Research Briefing

Powered by Gemini · 2026-04-08

Eiko is a microcap gamble on the successful integration of a single, potentially transformative acquisition.

Research Confidence
5.0/10Moderate
OPERATOR-DRIVEN1M: -9.6%, 3M: -2.73%, 6M: 1.35% indicates consolidation with recent weakness.P/E of 21.63x vs Industry P/E of 29.2x suggests fair valuation.

WHAT'S HAPPENING NOW (last 2-4 weeks)

Eiko Lifesciences' trading window closed on April 1st, 2026, in anticipation of the year-end financial results. The stock is down -23.6% from its 52-week high.

CORE STORY (THE REAL GAME)

Eiko is trying to transform from a specialty chemical and API supplier into an integrated pharma player. The market's watching if they can execute the SSM Formulations acquisition and scale up finished dosage production.

Why Now
  • SSM Formulations acquisition approved in Dec 2025
  • Q3 profit surge of 239.29%
  • Trading window closed ahead of results
Potential Catalysts
  • Successful integration of SSM Formulations
  • Significant order wins in formulations
  • Capacity expansion at SSM facility
Key Risks
  • Microcap liquidity risk
  • Integration risk of SSM
  • Reliance on single acquisition for growth
Institutional Activity

Promoter holding increased slightly by 0.43%. No FII/DII activity.

Macro Context

Indian specialty chemicals sector projected to grow, but faces global economic uncertainty and high energy costs.

Cash Flow Quality

Free Cash Flow 5Y: ₹None Cr suggests poor cash conversion.

3–6 Month Outlook

Eiko's 3-6 month outlook depends on the successful integration of SSM Formulations and ability to scale up production. Failure to do so will result in a significant correction.

Primary Thesis Risk

Failure to integrate SSM Formulations will obliterate the bull case.

For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.

Returns & Performance

Return on Equity (ROE)

N/A

Profit generated per ₹1 of shareholder equity

Return on Capital (ROCE)

N/A

Returns generated on total capital deployed

Oper. Profit Margin (5Y Avg)

N/A

Average operating profit margin over 5 years

Dividend Yield

0.00%

Annual dividend as % of current share price

Eiko Lifesciences Ltd Valuation Check

Good

Price to Earnings (P/E)

21.63x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

29.20x

Average P/E of all peers in this sector

Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Shareholding Pattern

Excellent

Promoter Holding

37.17%

% shares held by company founders/management

Poor

FII Holding

0.00%

% shares held by foreign institutional investors

Poor

DII Holding

0.00%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Excellent

Profit Growth (Quarterly YoY)

285.71%

Net profit growth vs same quarter last year

Excellent

Revenue Growth (Quarterly YoY)

43.01%

Revenue growth vs same quarter last year

Excellent

Revenue Growth (5-Year CAGR)

29.35%

Compounded annual revenue growth over 5 years

Excellent

EPS Growth (5-Year CAGR)

20.61%

Earnings per share growth over 5 years

Excellent

Net Profit Growth (5-Year CAGR)

25.18%

Compounded annual net profit growth over 5 years

Balance Sheet Health

Excellent

Debt to Equity Ratio

0.02x

Total debt ÷ equity. Below 0.5 = financially healthy

Excellent

Interest Coverage Ratio

20.84x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

N/A

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Eiko Lifesciences Ltd Fundamental Analysis & Valuation Benchmarking

Educational evaluation of EIKO across key market metrics for learning purposes.

Positive Indicators

9 factors identified

Attractive Valuation (P/E: 21.63 vs Industry: 29.20)

Observation: Trading at discount to industry peers.

Analysis: P/E below industry average may present value opportunity.

Robust Profit Growth (285.71%)

Observation: Strong year-over-year profit expansion demonstrates business momentum.

Analysis: Profit growth >20% indicates effective execution and market opportunity capture.

Strong Revenue Growth (43.01%)

Observation: Healthy sales growth indicates market demand and execution capability.

Analysis: Revenue growth >15% suggests strong market position and growth potential.

Consistent Growth Track Record (29.35% CAGR)

Observation: Strong 5-year sales compound annual growth rate.

Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.

Excellent EPS Growth (20.61% CAGR)

Observation: Outstanding 5-year earnings per share compound growth.

Analysis: EPS CAGR >15% indicates strong wealth creation potential.

Strong Profit Growth Track Record (25.18% CAGR)

Observation: Consistent 5-year profit compound annual growth rate.

Analysis: Profit CAGR >15% demonstrates scalable business model.

Conservative Debt Levels (D/E: 0.02)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns.

Strong Interest Coverage (20.84x)

Observation: Earnings comfortably cover interest obligations.

Analysis: Interest coverage >5x indicates low financial distress risk.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

1 factors identified

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.

Eiko Lifesciences Ltd vs Specialty Chemicals Peers

Peer Comparison - Specialty Chemicals

Compare Eiko Lifesciences Ltd with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
51/100
53
₹69.89
21.6
Average
0.0
Excellent
25.18%
Excellent
29.35%
Excellent
0.00%
60.4/100
1457
₹149466.57
66.6
Average
23.05%
Excellent
29.84%
Excellent
0.1
Excellent
12.63%
Good
12.49%
Good
0.68%
51.5/100
3612
₹37241.99
54.8
Average
8.29%
Poor
9.89%
Poor
0.2
Excellent
21.05%
Excellent
12.69%
Good
0.09%
40.6/100
6999
₹29462.02
66.3
Average
11.52%
Average
11.68%
Average
0.3
Excellent
-6.59%
Poor
17.22%
Excellent
0.21%
40.2/100
1670
₹21083.64
39.7
Average
13.36%
Average
16.28%
Good
0.2
Excellent
2.02%
Average
14.38%
Good
0.49%
52/100
3330
₹17807.40
46.3
Average
13.73%
Average
18.02%
Good
0.0
Excellent
57.98%
Excellent
14.83%
Good
0.49%
Atul Ltd...
ATUL500027
50.5/100
6686
₹17066.13
31.5
Average
9.10%
Poor
12.81%
Average
0.0
Excellent
-5.82%
Poor
6.41%
Good
0.43%
57.2/100
1307
₹16256.72
35.0
Average
15.75%
Good
20.61%
Excellent
0.0
Excellent
4.46%
Average
16.92%
Excellent
0.48%
37.5/100
1328
₹14036.52
92.8
Average
3.32%
Poor
7.33%
Poor
0.4
Excellent
11.97%
Good
22.13%
Excellent
0.06%
41.9/100
471
₹13796.68
51.3
Average
6.03%
Poor
6.32%
Poor
0.7
Good
-9.09%
Poor
11.68%
Good
0.26%
60.5/100
4492
₹13359.76
33.4
Average
19.47%
Good
26.39%
Excellent
0.0
Excellent
20.04%
Excellent
16.93%
Excellent
0.25%

Eiko Lifesciences Ltd PE Ratio History

Historical price-to-earnings ratio for EIKO — last 5 years

YearEPS (₹)Price (₹)P/E Ratio
FY 20251.62₹55.0534x
FY 20240.73₹62.7485.9x

P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.

Eiko Lifesciences Ltd Quarterly Performance

Latest quarterly metrics for EIKO — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

43.01%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

285.71%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

29.35%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

25.18%

Compounded annual net profit growth over 5 years

Eiko Lifesciences Ltd Technical Indicators

SMA 50, SMA 200, RSI and volume signals for EIKO — calculated from daily price history

67RSI 14
Neutral — RSI 67

Momentum is balanced — neither overbought nor oversold.

SMA 50
51
▲ Price above SMA 50 — Short-term bullish
SMA 200
52
▲ Price above SMA 200 — Long-term uptrend
30-Day Avg Volume
14K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Eiko Lifesciences Ltd Financial Statements

Annual income statement, balance sheet and cash flow for Eiko Lifesciences Ltd (EIKO) — sourced from NSE/BSE filings.

Loading Financial Statements...

Fetching financial data for Eiko Lifesciences Ltd

About EIKO (Eiko Lifesciences Ltd)

Eiko Lifesciences Ltd is a dynamic force in the specialty chemicals arena, meticulously crafting high-value ingredients and solutions for diverse global industries. Focused on prec...ision and innovation, EIKO leverages cutting-edge research and development to synthesize complex molecules, catering to niche applications where quality and performance are paramount. From specialized agrochemical components that enhance crop yields to advanced pharmaceutical intermediates that accelerate drug discovery, EIKO's comprehensive portfolio is designed to meet the evolving needs of its discerning clientele. The company prides itself on its commitment to sustainable practices, employing green chemistry principles to minimize environmental impact throughout its manufacturing processes. EIKO's strategic divisions synergistically operate, contributing to a robust and vertically integrated business model. The agrochemical division develops novel chemistries for crop protection, while the pharmaceutical arm synthesizes critical intermediates for drug formulations. EIKO's foray into oleo chemicals allows the company to offer bio-based solutions derived from natural oils and fats. In food additives, the organization is actively in manufacturing high-quality ingredients to boost and improve food production. Moreover, the company's dedication extends beyond production, encompassing comprehensive services such as research, development, logistics, and efficient distribution channels. This holistic approach ensures seamless delivery of tailored solutions to clients across geographical boundaries. Driven by a customer-centric philosophy, EIKO invests heavily in building strong, collaborative partnerships. The company's team of experienced chemists and engineers works closely with clients, providing technical support, customized formulations, and reliable supply chain management. EIKO's commitment to quality is unwavering, adhering to stringent regulatory standards and employing rigorous quality control measures at every stage of production. Through continuous innovation, operational excellence, and a steadfast dedication to customer satisfaction, EIKO is poised to further solidify its position as a trusted and reliable provider of specialty chemicals worldwide.

Company Details

Symbol:EIKO
Industry:Specialty Chemicals
Sector:Specialty Chemicals

Key Leadership

Mr. Jaid Ismail Kojar
Chief Financial Officer
Mr. Chintan Bharatbhai Doshi
Company Secretary & Compliance Officer
Mr. Sumukh Prabhakar Vartak
Whole Time Director

EIKO Share Price: Frequently Asked Questions

What is the current share price of Eiko Lifesciences Ltd?

Eiko Lifesciences Ltd (EIKO) trades at ₹52.95 on NSE and BSE. Market cap ₹69.89 (Cr). Educational data only.

What is the P/E ratio of Eiko Lifesciences Ltd?

Eiko Lifesciences Ltd has a P/E of 21.63x vs industry average 29.20x.

What is the Bull Run score for Eiko Lifesciences Ltd?

Eiko Lifesciences Ltd has a Bull Run score of 51/100 based on 25+ financial parameters.

Does Eiko Lifesciences Ltd pay dividends?

Eiko Lifesciences Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.

What is the ROE of Eiko Lifesciences Ltd?

Eiko Lifesciences Ltd has ROE of N/A. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Eiko Lifesciences Ltd?

Eiko Lifesciences Ltd has debt-to-equity of 0.02.

Is Eiko Lifesciences Ltd a good investment?

Bull Run gives Eiko Lifesciences Ltd a score of 51/100. This is not investment advice — consult a SEBI-registered advisor.